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Abstract 
Folic acid is used in dengue patients. Our study aims to compare the duration of recovery of 
thrombocytopenia in patients with dengue infection who received folic acid and those who 
did not. We retrospectively reviewed the medical records of adult patients admitted over six 
years with a diagnosis of dengue. Of 2,216 patients, 1464 fulfilled the inclusion 
criteria. Group A were those patients who received folic acid and group B were those who 
did not. 1322 (90.3%) patients received folic acid. Mean time period required for platelets to 
double the nadir was 1.7 (± 2.2) days days in both groups A and B (p value 0.89). In 
conclusion, there is no significant difference in the recovery of thrombocytopenia in 
patients with dengue fever who received folic and those who did not receive folic acid. 
  
Introduction 
South Asia has been declared as an endemic area of dengue infection by the World Health 
Organization (WHO). Pakistan has been hit by several dengue epidemics since 1994 and now 
is an endemic area.(1) Despite being a growing threat to almost whole world there is still no 
specific treatment for dengue infection, and treatment largely remains supportive. Several 
specific treatments have been tried in patients with no robust data to suggest any 
therapeutic options as standard. Such include steroids,(2) calcium and vitamin D 
supplements, (3) papaya leaves extract, (4) chloroquine, (5)immunoglobulin,(6)  folic acid (7, 8) and 
so on. Many of these treatment regimens focus on rapid improvement of 
thrombocytopenia. 
Folic acid is frequently used without any scientific basis.(7) Up to 30% of paediatric patients 
with dengue infection received folic acid in addition to other supportive measures in a 
typical Indian study.(8) The rationale for folic acid use in dengue is not clear. It may 
be prescribed because of its low cost, its few adverse effects and its role as 
a haematinic. Interestingly, one study (9) showed that the replication of dengue viruses 
inhibited by methotrexate was restored by folinic acid, a natural folate. Hence it is possible 
that folic acid may actually be deleterious in dengue!  
  
Materials and methods 
This study was conducted at the Department of Medicine of the Aga Khan University 
Hospital Karachi, Pakistan, which is a 700 bed tertiary care academic medical institute 
receiving patients not only from Karachi, which is the most populous city of Pakistan with an 
estimated population in excess of 20 million, but also from rest of the country.  
Ethical approval was obtained for the study from the institutional Ethical Review Committee 
(4095-Med-ERC-16). 
  
Our primary objective was to determine the duration of recovery of thrombocytopenia in 
patients with dengue infection who received and did not receive folic acid during 
hospitalization. The secondary objectives were to compare the mortality, ICU stay, length of 
stay, and creatinine among patients with dengue infection between the two groups. We 
reviewed the medical records of all patients over 16 years of age admitted in the 
department of Medicine at our hospital from 1st June 2007 to 31st December 2013 with a 
diagnosis of dengue infection who had evidence of doubling of platelets from an earlier 
nadir. All patients who had received platelet transfusion were excluded from the study. A 
case of dengue fever was defined as a patient admitted with fever who had a positive 
dengue IgM antibody or dengue antigen test. The lowest platelet count after admission was 
recorded. Subsequent platelet counts double the nadir were also recorded during the 
hospital stay, as were creatinine levels at the time of admission and discharge, and the 
length of hospital stay.  Group A were those patients who received folic acid and group B 
were those who did not. 
Data regarding frequency of deaths and ICU stay were also collected and compared 
between the two groups and compared. P values <0.05 were deemed significant. Fisher’s 
exact T test and Mann-Whitney U test were used to compute P values. All analyses were 
conducted by using the Statistical Package for Social Science SPSS 19.0 (IBM Corp. Released 
2010. IBM SPSS Statistics for Windows, Version 19.0. Armonk, NY: IBM Corp.). 
 
Results 
Medical records of 2,216 adult patients who were admitted in our hospital with a diagnosis 
of dengue infection from 1st June 2007 to 31stDecember 2013 were analysed. 1464 fulfilled 
our inclusion criteria. Their mean age was 36.6 (± 15.0) years. The mean lowest platelet 
count was 35.5 (± 13.2) x 109/L. The mean doubled platelet count from nadir 
was 81.3 (± 35.2) x 109/L.  The dose of folic acid received by each patient was 5mg per day 
(Table 1). 
Out of the 1464 patients, 1322 (90.3%) received folic acid. The mean time period required 
for platelets to double the nadir was 1.7 (± 2.2) days and 1.7 (± 2.2) days, respectively, 
in groups A and B (P = 0.89) (Table 2). Only 11 patients required ICU admission and all of 
them belonged to group A (P = 0.99). Similarly, there were only two patients who died and 
both were of group A (P = 0.99).  
The mean creatinine at admission was 107.9 (± 31.7) and 105 (± 31.1) µmol/L in group A and 
B respectively (P = 0.30), and at discharge 107 (± 31.5) µmol/L and 105.9 (± 
35) µmol/L, respectively (P = 0.69).  
Data extracted are shown in Tables 1 & 2. 
 
  
  
  
  
  
  
  
  
  
  
  
Table 1. Baseline characteristics of study population (n=1464) 
  
Mean age 36.5 ± 15.0 years 
Mean lowest platelet count 35.5 ± 13.2 x 109/L 
Mean doubled platelet count from nadir 81.3 ± 35.2 x 109/L 
Mean platelet doubling time 1.7 ± 2.2 days 
Dose of folic acid received by each patient 5 mg per day 
Mean length of hospital stay (days) 3.4 ± 3.9 
Mean creatinine at admission (µmol/L) 107.5 ± 31.6 
Mean creatinine at discharge (µmol/L) 106.8 ± 31.8 
  
 Table 2. Frequency and comparison of doubling time of platelets from nadir, creatinine, 
length of stay, ICU admission and mortality status in group A (dengue patients who received 
folic acid) and B (dengue patients who did not receive folic acid) (n=1464) 
  
  Group A Group B p value 
Mean age (years) 36.6 ± 14.9 35.9 ± 15.4 
  
0.38 
  
Mean lowest platelet 
count (x 109/L) 
35.7 ± 13.3 34.5 ± 12.6 0.37 
Mean doubled platelet 
count from nadir (x 109/L) 
81.5 ± 35.3 79.5 ± 33.7 0.52 
Mean Platelets doubling 
time from nadir (days) 
1.7 ± 2.2 1.7 ± 2.2 0.89* 
Mortality 
    Yes 
    No 
  
2 (0.15%) 
1320 (99.84%) 
0 (0%) 
142 (100%) 
0.99** 
ICU admission  
(no. of patients) 
    Yes 
    No 
  
  
11 (0.83%) 
1311 (99.16%) 
  
  
0 (0%) 
142 (100%) 
0.99** 
Mean length of hospital 
stay (days) 
3.4 ± 3.9 3.6 ± 3.9 0.75* 
Mean creatinine at 
admission (µmol/L) 
107.8 ± 31.7 105 ± 31.1 0.30 
Mean creatinine at 
discharge (µmol/L) 
107 ± 31.5 105.8 ± 35 0.69 
*Mann-Whitney U test 
**Fisher’s Exact test 
   
Discussion 
Our study showed that there was no significant difference in the duration of recovery of 
thrombocytopenia whether folic acid was taken or not. There was likewise no significant 
difference in length of hospital stay.  
There is no specific treatment available for dengue fever and good supportive treatment is 
the mainstay of management,(10) but the use of several drugs has been proposed. 2-6) Trials in 
vitro including anti-TNF antibodies, (11) celgosivir and ribavirin (antiviral agents),(12, 13) have been 
undertaken without conclusive success.   
Thrombocytopenia, being the most important manifestation of dengue, has been the target 
of most of these studies. Use of folic acid, despite the absence of scientific justification, is 
virtually ubiquitous. (7, 8)    
 
Conclusion 
To the best of our knowledge, ours is the first of its kind assessing the effects of folic acid 
supplementation on several outcomes of dengue. This study presents only retrospective 
data, and we compared the doubling time from a nadir value of platelets rather than 
absolute values as a marker of recovery of thrombocytopenia. There is a need 
for prospective controlled studies to compare the effects of folic acid on both the recovery 
of thrombocytopenia and other parameters in patients with dengue. However, it seems that 
there is no significant value in the use of folic acid regarding recovery of thrombocytopenia 
in dengue.  
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